Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Veritas In Silico Inc. ( (JP:130A) ) has issued an announcement.
Veritas In Silico Inc. and Mitsubishi Gas Chemical have entered a joint research agreement to develop nucleic acid drugs and establish manufacturing methods using Quality by Design (QbD) principles. This collaboration aims to enhance drug discovery and manufacturing processes, with Veritas In Silico leveraging its ibVIS® platform. The agreement aligns with Veritas In Silico’s growth strategy, contributing significantly to its KPIs and expected revenue, while also advancing its in-house drug pipeline.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the biotechnology industry, focusing on drug discovery, particularly nucleic acid drugs. The company utilizes its proprietary drug discovery platform, ibVIS®, which is optimized for mRNA targets and applicable to nucleic acid drugs. Veritas In Silico has partnered with various pharmaceutical companies and holds patents in Japan for its ASO compounds.
Average Trading Volume: 62,309
Technical Sentiment Signal: Sell
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.